Carisma Therapeutics Inc
CARM0.154USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
6.43MMarket Cap
LossP/E TTM
More Details of Carisma Therapeutics Inc Company
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. The Company seeks to apply the ability to engineer macrophages and monocytes, either in vivo or ex vivo. Its proprietary chimeric antigen receptor macrophages(CAR-M) platform uses CARs to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted antitumor immunity. It is developing a pipeline of product candidates which includes CT-1119, In Vivo CAR-Macrophage: GPC3+ Solid Tumors, In Vivo CAR-Macrophage: Oncology Targets, and CT-2401 (Liver Fibrosis). CT-2401 is a product candidate in development for liver fibrosis, and CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.
Carisma Therapeutics Inc Info
Ticker SymbolCARM
Company nameCarisma Therapeutics Inc
IPO dateFeb 06, 2014
CEOKelly (Steven)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endFeb 06
Address3675 Market Street
CityPHILADELPHIA
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code19104
Phone12674916422
Websitehttps://sesenbio.com/
Ticker SymbolCARM
IPO dateFeb 06, 2014
CEOKelly (Steven)
Company Executives of Carisma Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Natalie Mcandrew
Ms. Natalie Mcandrew
Vice President - Finance, Treasurer and Secretary
Vice President - Finance, Treasurer and Secretary
--
--
Mr. Sanford (Sandy) Zweifach, CPA
Mr. Sanford (Sandy) Zweifach, CPA
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Ms. Marella Thorell
Ms. Marella Thorell
Director
Director
--
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Director
Director
--
--
Mr. Steven (Steve) Kelly
Mr. Steven (Steve) Kelly
Interim Chief Executive Officer
Interim Chief Executive Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Natalie Mcandrew
Ms. Natalie Mcandrew
Vice President - Finance, Treasurer and Secretary
Vice President - Finance, Treasurer and Secretary
--
--
Mr. Sanford (Sandy) Zweifach, CPA
Mr. Sanford (Sandy) Zweifach, CPA
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Ms. Marella Thorell
Ms. Marella Thorell
Director
Director
--
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Director
Director
--
--
Mr. Steven (Steve) Kelly
Mr. Steven (Steve) Kelly
Interim Chief Executive Officer
Interim Chief Executive Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Modernatx Inc
12.09%
Longview Innovation Corp
6.48%
Wellington Partners Venture Capital GmbH
5.49%
SymBiosis Capital Management, LLC
5.30%
Abbvie Biotechnology Ltd
4.44%
Other
66.20%
Shareholders
Shareholders
Proportion
Modernatx Inc
12.09%
Longview Innovation Corp
6.48%
Wellington Partners Venture Capital GmbH
5.49%
SymBiosis Capital Management, LLC
5.30%
Abbvie Biotechnology Ltd
4.44%
Other
66.20%
Shareholder Types
Shareholders
Proportion
Corporation
26.53%
Venture Capital
10.79%
Endowment Fund
2.99%
Investment Advisor
2.02%
Investment Advisor/Hedge Fund
0.93%
Hedge Fund
0.73%
Research Firm
0.14%
Individual Investor
0.03%
Other
55.83%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
132
7.37M
30.61%
--
2025Q3
140
7.37M
30.94%
-2.92M
2025Q2
141
11.68M
36.22%
-1.59M
2025Q1
146
13.27M
37.49%
-2.39M
2024Q4
170
13.31M
35.74%
+191.33K
2024Q3
174
13.12M
36.86%
-929.70K
2024Q2
182
14.05M
41.77%
-2.41M
2024Q1
178
16.47M
32.22%
+3.08M
2023Q4
184
16.96M
23.96%
+131.55K
2023Q3
206
17.32M
26.07%
-178.83K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Modernatx Inc
5.06M
12.11%
--
--
Jul 31, 2025
Longview Innovation Corp
2.71M
6.49%
--
--
Jul 31, 2025
Wellington Partners Venture Capital GmbH
2.30M
5.5%
--
--
Jul 31, 2025
SymBiosis Capital Management, LLC
2.22M
5.3%
--
--
Jul 31, 2025
Abbvie Biotechnology Ltd
1.86M
4.44%
-893.98K
-32.51%
Mar 31, 2025
Merck & Co Inc
1.47M
3.53%
--
--
Jun 30, 2025
University of Pennsylvania Trustees
1.25M
3%
--
--
Sep 30, 2024
The Vanguard Group, Inc.
350.32K
0.84%
-1.05M
-74.90%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
336.79K
0.81%
-64.84K
-16.14%
Jun 30, 2025
Renaissance Technologies LLC
329.29K
0.79%
+75.63K
+29.82%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 2000 ETF
0%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
Proshares Ultra Russell 2000
0%
View more
Avantis US Small Cap Equity ETF
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 06, 2023
Merger
20→1
Mar 06, 2023
Merger
20→1
Mar 06, 2023
Merger
20→1
Mar 06, 2023
Merger
20→1
Date
Type
Ratio
Mar 06, 2023
Merger
20→1
Mar 06, 2023
Merger
20→1
Mar 06, 2023
Merger
20→1
Mar 06, 2023
Merger
20→1
FAQs
Who are the top five shareholders of Carisma Therapeutics Inc?
The top five shareholders of Carisma Therapeutics Inc are:
Modernatx Inc holds 5.06M shares, accounting for 12.11% of the total shares.
Longview Innovation Corp holds 2.71M shares, accounting for 6.49% of the total shares.
Wellington Partners Venture Capital GmbH holds 2.30M shares, accounting for 5.50% of the total shares.
SymBiosis Capital Management, LLC holds 2.22M shares, accounting for 5.30% of the total shares.
Abbvie Biotechnology Ltd holds 1.86M shares, accounting for 4.44% of the total shares.
Modernatx Inc holds 5.06M shares, accounting for 12.11% of the total shares.
Longview Innovation Corp holds 2.71M shares, accounting for 6.49% of the total shares.
Wellington Partners Venture Capital GmbH holds 2.30M shares, accounting for 5.50% of the total shares.
SymBiosis Capital Management, LLC holds 2.22M shares, accounting for 5.30% of the total shares.
Abbvie Biotechnology Ltd holds 1.86M shares, accounting for 4.44% of the total shares.
What are the top three shareholder types of Carisma Therapeutics Inc?
The top three shareholder types of Carisma Therapeutics Inc are:
Modernatx Inc
Longview Innovation Corp
Wellington Partners Venture Capital GmbH
Modernatx Inc
Longview Innovation Corp
Wellington Partners Venture Capital GmbH
How many institutions hold shares of Carisma Therapeutics Inc (CARM)?
As of 2025Q4, 132 institutions hold shares of Carisma Therapeutics Inc, with a combined market value of approximately 7.37M, accounting for 30.61% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.33%.
What is the biggest source of revenue for Carisma Therapeutics Inc?
In --, the -- business generated the highest revenue for Carisma Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
